StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$1.94−0.10 (-4.90%)

Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –

Niagen Bioscience pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Niagen Bioscience's pe ratio was 11.6× on Nov 11, 2026, against 28.2× a year earlier. Over the last 2 years it ranged from 11.6× to 772.0×, with a median of 28.2×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202611.6×−14.9
2025Dec 31, 202526.5×−504.0
2024Dec 31, 2024530.5×–

More Niagen Bioscience figures

See a number that looks wrong?